The power to predict can strengthen the ability to heal and prevent disease. That's why AutoGenomics, a Prescient Medicine company, is dedicated to uncovering critical insights that enable more informed, more effective care. We see this as the next frontier in healthcare, and we're passionate about bringing it to life today. The need is critical, the technology is ready, and the time is now.
Through our expertise in pharmacology, chemistry, pathology, pharmacogenomics, and toxicology, we’ve created powerful tests, instruments and analytics that deliver the right information necessary to make the correct choice at the appropriate time. With actionable results in hand, physicians can better prescribe compatible therapies and also predict how a patient might react to potential treatment options.
Dr. Keri Donaldson – Chief Executive Officer and Head of Science / R&D
Dr. Donaldson’s work as Medical Director and CEO of Prescient Medicine is fueled by an extensive background in the fields of pathology, genomics, and diagnostics. An active ad hoc reviewer and consultant, Dr. Donaldson has earned a reputation as an innovative member of the medical community and garnered key positions within respected institutions and national committees. Throughout his time with Penn State College of Medicine, he’s served as Assistant Professor of Pathology (also at Hershey Medical Center), Assistant Professor of Public Health Sciences (a joint appointment also at Hershey Medical Center), Assistant Professor of Medicine, and Assistant Professor of Biochemistry. He was certified as a diplomate of both the American Board of Pathology and the National Board of Medical Examiners, and is a frequent guest speaker at regional and national symposia. Dr. Donaldson holds a BS from Pennsylvania State University, an MD from Temple University School of Medicine, and a master of science in clinical epidemiology (MSCE) from the University of Pennsylvania School of Medicine.
Brian Eichenberger, Head of Operations and Technology
With more than 20 years of experience in systems development, implementation and integration, Brian delivers a wide range of expertise in his work with Prescient Medicine. He serves as head of the Technology Team in the development of laboratory information systems, analytics, and smart app platforms. His responsibilities include the vision, strategy, and implementation of all aspects of information technology, telecommunications, and client operations. Before joining Prescient Medicine, Brian held multiple leadership positions at CVS Health, including a Senior Director role in which he managed day-to-day client operations and technology development for an $18 billion client portfolio with a $300 million technology budget. His time spent supporting automating and initiatives within new health plan features, regulatory and compliance controls, disease management applications, prescription fulfillment, and adjudication solutions earned him multiple “CVS Breakthrough” awards in recognition of technology achievements and innovation. Brian has a Bachelor of Arts in economics/accounting from the University of Illinois.
Kevin Stineman, Head of Sales and Marketing
Kevin is a leader, executive and general manager with 20+ years of experience building and leading commercial teams and operations. Kevin comes to Prescient from Morningstar, Inc, a global investment research company, where he spent 15 years and most recently led the Global Markets Group. In this role, he was responsible for operations in 26 countries with 400+ employees and annual revenue of $225 million. Over his career, Kevin has held leadership roles responsible in client service, software operations, product management, sales management and P&L management. Kevin has demonstrated his ability to enter and build businesses in new markets through developing and executing go-to-market strategies across a variety of business lines. He excels at building high-performing teams in marketing, sales, product development and service to drive revenue growth, scalability and profitability. Kevin received his Bachelor of Arts from Dartmouth College in 1994 and an MBA in general management, marketing and technology from the Kellogg School of Management in 2002.
Shailendra (Shelley) Singh, Ph.D., Co-founder, Vice President, System Development
Dr. Singh has been Vice President, System Development of AutoGenomics since its founding in April 1999. Dr. Singh has 34 years of experience in software engineering, systems development and integration, the last 29 of which have been spent in the healthcare industry and participating in the invention and development of eight medical instruments. Dr. Singh has held the position of Vice President of Systems Development at Sequenom, Inc., PB Diagnostics Systems, Inc. and Behring Diagnostics, Inc. Dr. Singh received a B.S. in electrical engineering, an M.E. in electrical engineering and a Ph.D. in electrical engineering from Southern Methodist University.
Evelyn Lopez, Vice President, Regulatory Affairs
Mrs. Lopez joined AutoGenomics in 2006 and has over 30 years of regulatory/clinical affairs/quality assurance experience in medical devices and pharmaceuticals companies. Her experience includes US and international regulations related to clinical trials/premarket submissions (PMA, IDE, 510k, MDD/IVDD) and quality systems (FDA QSR, ISO), as well as activites related to strategic planning, contract manufacturing, and mergers/acquisitions. Mrs. Lopez served as Vice President, Regulatory & Quality Assurance for Novatrix Biomedical, Director of Clinical Affairs at Micro Therapeutics, and Director of Regulatory Affairs at Cryogen. Mrs. Lopez holds a B.S. in Chemical Engineering from the Philipines, and a M.S. in Operations Research from Stanford University.
Sherman Chang, Ph.D., Vice President, R&D Chemistry
Dr. Chang joined AutoGenomics as Senior Director of R&D Chemistry in 2013 and was appointed as Vice President of R&D Chemistry in January 2016. Prior to that, Dr. Chang was Senior Director of R&D at DermTech International (a biotech startup company in La Jolla, CA) where he developed a disruptive non-invasive melanoma cancer diagnostic test currently used in the market. Dr. Chang brings over 20 years of experience in R&D and In Vitro Diagnostics (IVD). Dr. Chang was the recipient of the 2017 AACC industry division poster award/certificate for genetic risk assessment of Opioid Addiction. Dr. Chang holds a B.S.in Pharmacy & M.S. in Biochemistry from National Taiwan University and a Ph.D. in Molecular Biology from University of Pittsburgh. Dr. Chang completed his post-doctoral research training at the Salk Institute and UCSD.
Dr. Laurence M. Demers, Medical Director
A clinical biochemist at Prescient Medicine, Dr. Laurence M. Demers (DABCC, FACB) is an accomplished researcher, author of medical texts, and clinical trial investigator—within both the pharmaceutical and in vitro diagnostic industries. His research is concentrated in molecular diagnostics, laboratory automation, thyroid disease, metabolic bone disease and breast cancer, leading to authorship on over 720 publications. Dr. Demers’s past and present board memberships include standouts such as President of the American Association for Clinical Chemistry, President of the National Academy of Clinical Biochemistry, the founding Director of Clinical Chemistry at the M.S. Hershey Medical Center, founding Director of the Core Endocrine Laboratory in the Pennsylvania State University Hospital, Chairman of the Board of Trustees of Merrimack College, and Director of the Pennsylvania State Clinical Research Center Core Laboratory. A diplomate of the American Board of Clinical Chemistry and a fellow of the National Academy of Clinical Biochemistry, Dr. Demers holds a PhD in biochemistry from the State University of New York and an AB in biology from Merrimack College—where in 2011 he was awarded an honorary doctor of science. Dr. Demers is a distinguished professor emeritus of medicine and pathology at the Pennsylvania State University College of Medicine
Dongmei Wang, Vice President, Finance
Dongmei Wang has served as Vice President of Finance of AutoGenomics since 2017. She works closely with senior management in overseeing all aspects of the company’s finances, including business risk assessment and management, financial analysis and audits, tax compliance, monthly close, preparation of financial statements, and reporting to the board. Ms. Wang brings to the company over eighteen years of financial and human resources management experiences with a focus on managing cash flow and vendor relations, developing policies and procedures to improve performance and productivity. Before joining the company, Ms. Wang has worked in public accounting at McGladrey LLP and in senior financial management positions at other service and biotech companies, most recently in Reproductive Sciences Medical Center, San Diego. Ms. Wang holds a certificate of public accountancy with inactive license, has a Bachelor of Science degree with distinction in accounting from the University of Minnesota, and a master’s degree in International Management from University of St. Thomas.
Dr. Larissa Karnaoukhova, Ph.D, Director of Operations, Reagent Manufacturing and Supply Chain
Dr. Karnaoukhova has served as Director of Operations, Reagent Manufacturing and Supply Chain since November 2016. Prior to this role, she served as Customer Service Technical Support Scientist since joining the company in 2012. Dr. Karnaoukhova has over 20 years of operational strategy, product development, sales and customer service experience in life sciences and molecular diagnostics and has held various scientific and business development positions with Life Technologies Invitrogen Corporation, VWR International, Gene Express and Genlantis. She holds Master of Science in Physics from Moscow State University, Russia, Ph.D in Molecular Biology from University of Victoria, Canada and Master of Business Administration from University of California, San Diego.
Shafie Kureshy, Director of Operations: Engineering and Manufacturing
Shafie Kureshy joined AutoGenomics in 2001 and is an integral part of the Systems Development and Operations teams. Shafie played a key role leading a team of engineers to design and deploy the AutoGenomics instrument platforms and consumable lines. In an operational role, Shafie and his team oversee the production of instruments and performance of internal manufacturing operations. Prior to AutoGenomics, Shafie was part of the Engineering team at Behring Diagnostics developing immunoassay diagnostic instruments. Shafie has a Bachelors of Business Administration in IT from Baylor University.
Rastgo Shali, Director of Technical Support
Rastgo joined AutoGenomics in 2006 as part of the Systems Development team where he was instrumental in developing key technologies used in the Infiniti Plus and HTS. Shortly after, Rastgo transitioned to the Technical Support team where he has been responsible for leading and developing a team to train new customers and assist existing customers with integrating molecular diagnostic testing into their labs. Prior to AutoGenomics, Rastgo has held an extensive career in pre and post technical and application support, digital electronics, and CAE applications. Rastgo holds a B.Sc. of Electrical Engineering from University of Technology in Iraq and a M.Sc. in Electrical and Computer Engineering from San Diego State University.